METROPOLIS Metropolis Healthcare Q3 FY25 results (Oct–Dec 2024) and concall
Metropolis Healthcare reported a resilient Q3 FY25 with 10.9% YoY revenue growth to INR 323 crores, driven by strong B2C performance (up 15% YoY). EBITDA grew 9.4% to INR 71.6 crores, with a margin of 22.2%. The company is progressing with the acquisition of Core Diagnostics, expected to be EPS accretive from year one, and is actively pursuing further inorganic growth opportunities. While Q3 saw a temporary dip in acute patient volumes and margin dilution from the Core acquisition is anticipated initially, management expects a rebound in Q4 and continued margin expansion post-integration.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 11 |
| EBITDA | 72 |
| Net profit | 31 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
